Summit Therapeutics INC Form 4 insider transactions

Summit Therapeutics' Chief Accounting Officer, Bhaskar Anand, was granted 75,000 stock options on January 12, 2025, which vest over four years.

Summit Therapeutics Co-Chief Executive Officer Robert Duggan reports changes in his beneficial ownership of company stock and options following his recent marriage.

Summit Therapeutics Co-Chief Executive Officer, Mahkam Zanganeh, filed a Form 4 detailing share transactions and beneficial ownership, including shares held directly, indirectly through trusts, and by her spouse.

Director Jeff Huber acquired stock options for 35,000 shares of Summit Therapeutics Inc. on January 2, 2025.

Director Yu Xia of Summit Therapeutics Inc. was granted stock options on January 2, 2025, as part of a director retainer plan.

Alessandra Cesano, a director at Summit Therapeutics Inc., was granted stock options on January 2, 2025, according to a Form 4 filing with the SEC.

Mostafa Ronaghi, a director of Summit Therapeutics Inc., was granted stock options to purchase 35,000 shares of common stock.

Director Kenneth Clark of Summit Therapeutics Inc. was granted stock options on January 2, 2025, as part of his director retainer.

Robert Booth, a director of Summit Therapeutics Inc., acquired stock options on January 2, 2025, according to a Form 4 filing with the SEC.

Director Kenneth A. Clark acquired 200,000 stock options in Summit Therapeutics Inc. on October 11, 2024, according to a Form 4 filing.

Mahkam Zanganeh, Co-CEO of Summit Therapeutics, exercised warrants to purchase 315,681 shares of common stock at $1.58 per share.

Co-CEO Mahkam Zanganeh acquires 44,052 shares of Summit Therapeutics in a private placement at $22.70 per share.

Robert W. Duggan, Co-CEO of Summit Therapeutics, acquired 3,325,991 shares of common stock at $22.70 per share through a private placement, increasing his direct holdings to 551,695,096 shares.

Director Jeff Huber acquired 44,052 shares of Summit Therapeutics Inc. common stock through a private placement via Caspian Capital LLC.

Manmeet Singh Soni, COO and CFO of Summit Therapeutics, acquired 44,052 shares of common stock at $22.70 per share through a private placement.

Bhaskar Anand, Chief Accounting Officer of Summit Therapeutics Inc., acquired 22,026 shares of common stock in a private placement transaction.

Manmeet Singh Soni, COO and CFO of Summit Therapeutics Inc., reports the acquisition of 2,800,000 performance-based stock options that vested on August 23, 2024.

Summit Therapeutics CEO, Mahkam Zanganeh, acquired performance-based stock options on August 23, 2024, after the company met certain financial performance objectives.

Director Jeff Huber acquired stock options in Summit Therapeutics Inc. on June 27, 2024, as reported in a Form 4 filing with the SEC.

Director Mostafa Ronaghi received stock options from Summit Therapeutics Inc. on April 11, 2024.

Manmeet Singh Soni, Chief Operating Officer of Summit Therapeutics Inc., reports the acquisition of stock options.

Bhaskar Anand, Chief Accounting Officer of Summit Therapeutics Inc., was granted stock options on April 2, 2024.

Summit Therapeutics CEO Mahkam Zanganeh recently purchased additional shares of the company's common stock, signaling confidence in the firm's prospects.

Ankur Dhingra, CFO of Summit Therapeutics Inc., purchased 100,000 shares of common stock at an average price of $3.75 on March 26, 2024.